Recent Market Report: Global Psoriasis Therapeutics Market Trends 2012-2016

TechNavio's analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing uptake of biologics. The Global Psoriasis Therapeutics market has also been witnessing an increased focus on using combination therapies for treating psoriasis. However, the adverse side effects associated with psoriatic drugs could pose a challenge to the growth of this market.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/global-psoriasis-therapeutics-market-2012-2016

TechNavio's report, the Global Psoriasis Therapeutics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Psoriasis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include Amgen Inc., Pfizer Inc., Janssen Biotech Inc., and Abbvie Inc.

The other vendors mentioned in the report are AstraZeneca plc, Bristol Myers Squibb Co., Celgene Corp., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline plc, Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., and Novartis International AG

UCB S.A. Key questions answered in this report:

• What will the market size be in 2016 and what will be the growth rate?
• What are key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by key vendors?
• What are the strengths and weaknesses of each of these key vendors?

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/172952  

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/

Worldwide Business Survey: Global Stem Cell Anticancer Therapeutics Market Size 2012-2016

TechNavio's analysts forecast the Global Stem Anticancer Therapeutics market to grow at a CAGR of 11.48 percent over the period 2012-2016. Increasing investment in R&D is one of the key factors contributing to this market growth. The Global Stem Anticancer Therapeutics market has also been witnessing an increasing number of strategic alliances among vendors. However, stringent regulatory approval processes could pose a challenge to the growth of this market.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/global-stem-cell-anticancer-therapeutics-market-2012-2016

TechNavio's report, the Global Stem Anticancer Therapeutics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Stem Anticancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include Celgene Corp., Curis Inc., Exelixis Inc., Gamida Cell Ltd., Lonza Group, Merck & Co. Inc., OncoMed Pharmaceuticals Inc., Pfizer Inc., Roche Holding AG, Teva Pharmaceutical Industries Ltd., and Verastem Inc.

Key questions answered in this report:

• What will the market size be in 2016 and what will be the growth rate?
• What are key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by key vendors?
• What are the strengths and weaknesses of each of these key vendors?

1. Executive Summary

2. List of Abbreviations

3. Introduction

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/172954

4. Market Research Methodology

Market Research Process

Research Design

Research Methodology

5. Scope of the Report

Market Overview

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/

Global Business Survey: Trends in Therapeutic Partnering market Analysis

Description

The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2007 to mid 2013.

The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2007 to mid 2013. The majority of deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or access the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/trends-in-therapeutic-partnering

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapeutic targets. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of therapeutic partnering trends since 2007, together with insight into which companies are active in each of the thirty five leading therapeutic areas.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

To Buy The Copy of This Report Visit : http://www.marketresearchreports.biz/analysis/172528

The initial chapters of this report provide an orientation of therapeutic dealmaking.

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of therapeutic dealmaking since 2007, listing the top therapeutic areas for partnering by deal frequency and deal dollars committed by partnering companies.

              

Chapter 3 reviews the top pharma and biotech therapeutic partnering deals of 2007-2013 according to reported deal size.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/

Worldwide Business Survey: Global Industry Uterine Cancer Therapies and Diagnostic Market Size 2013 - 2019

Uterine cancer is a cancer of uterus and is classified into the following four types, namely uterine sarcomas, endometrial cancer, cervical cancer and gestational trophoblastic disease. These cancers arise from malignancies of connective tissues, endometrium and cervix uteri of the uterus. Uterine cancers are the fourth most common cancers among women overall.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/uterine-cancer-therapies-and-diagnostic-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019

According to American Cancer Society (ACS), uterine sarcoma accounts for 5% of the total global uterine cancer cases whereas endometrial cancer is most prevalent form of uterine cancer.  Both of these cancers can be diagnosed either by medical imaging techniques such as magnetic resonance imaging (MRI), ultrasound and CT scan or by histological examination of the tissues of uterus. Cervical cancer is one of the most common and fifth death-causing cancers in women. Presence of cervical cancer can be checked with the help of endometrial biopsy, colposcopy or a screening test called as Pap smear. Radiation therapies can be applied to cure cervical cancer as it is radiosensitive. In the worst case of infection, surgical removal of the uterus called as hysterectomy, is performed. Surgery combined with radiation therapies is often used to treat endometrial cancer. 

According to the surveys of World Health Organization (WHO), the prevalence of endometrial cancer is greater in the developed region such as the North American countries followed by European countries due to changing lifestyle of women. Prevalence of uterine cancer is more in women aged 50 years and above. The incidence of cervical cancer is greater in the developing countries such as India and China accounting for 80% of the total incidences. 

To Buy The Copy of This Report Visit : http://www.marketresearchreports.biz/analysis/171615

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/